1. Metabolic Enzyme/Protease
  2. Endogenous Metabolite
  3. Vasopressin

Vasopressin  (Synonyms: Arginine vasopressin; Antidiuretic hormone)

Cat. No.: HY-B1811 Pureté: 99.65%
Instruction de manipulation Technical Support

Vasopressin is a cyclic nonapeptide that is synthesized centrally in the hypothalamus. Vasopressin participates in the hypothalamic-pituitary-adrenal axis, and regulates pituitary corticotropin secretion by potentiating the stimulatory effects of corticotropin releasing factor. Vasopressin also can act as a neurotransmitter, exerting its action by binding to specific G protein-coupled receptors.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Synthèse de peptides personnalisée

CAS No. : 11000-17-2

Size Prix Stock Quantité
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
En stock
Solution
10 mM * 1 mL in DMSO En stock
Solid
5 mg En stock
10 mg En stock
25 mg En stock
50 mg En stock
100 mg En stock
200 mg   Obtenir un devis  
500 mg   Obtenir un devis  

* Veuillez sélectionner la quantité avant d'ajouter des articles.

This product is a controlled substance and not for sale in your territory.

Avis client

Based on 6 publication(s) in Google Scholar

Other Forms of Vasopressin:

Top Publications Citing Use of Products

    Vasopressin purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Oct 15:933:175262.

    Vasopressin (AVP) (10 μM; 48 h) increased neonatal primary rat cardiomyocyte surface areas.

    Vasopressin purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Oct 15:933:175262.

    Vasopressin (AVP) (10 μM; 48 h) increased mRNA expression levels of cardiomyocyte hypertrophy markers BNP, TRPC6, and β-MHC in cardiomyocytes.

    Vasopressin purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Oct 15:933:175262.

    Vasopressin (AVP) (10 μM; 48 h) markedly increased malondialdehyde (MDA) levels, an indicator of mitochondrial oxidative stress levels, in cardiomyocytes.

    Vasopressin purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Oct 15:933:175262.

    Representative fluorescent JC-1 images and quantification of mitochondrial membrane potential (MMP) levels, in terms of the ratio of green (representing JC-1 monomers, and therefore depolarization and lowered MMP) to red (representing JC-1 aggregates) JC-1 fluorescence, were obtained in Vasopressin (AVP) (10 μM; 48 h)-treated cardiomyocytes.

    Vasopressin purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Oct 15:933:175262.

    Vasopressin (AVP) (10 μM; 48 h) significantly decreased p-Mst1, the active phosphorylated form of Mst1, and nuclear Nrf2 protein levels in cardiomyocytes.

    Voir tous les produits spécifiques à Isoform Endogenous Metabolite:

    • Activité biologique

    • Pureté et documentation

    • Références

    • Avis client

    Description

    Vasopressin is a cyclic nonapeptide that is synthesized centrally in the hypothalamus. Vasopressin participates in the hypothalamic-pituitary-adrenal axis, and regulates pituitary corticotropin secretion by potentiating the stimulatory effects of corticotropin releasing factor. Vasopressin also can act as a neurotransmitter, exerting its action by binding to specific G protein-coupled receptors[1][2][3].

    IC50 & Target

    Human Endogenous Metabolite

     

    Cellular Effect
    Cell Line Type Value Description References
    A7R5 IC50
    10 nM
    Compound: vasopressin, VS2
    Tested for the TYR(Me)2 arginine-vasopressin as radioligand at 0.3 nM in A7r5 cells
    Tested for the TYR(Me)2 arginine-vasopressin as radioligand at 0.3 nM in A7r5 cells
    10.1016/S0960-894X(97)00050-4
    CHO EC50
    2 nM
    Compound: AVP
    Agonist activity at human vasopressin V1b receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay
    Agonist activity at human vasopressin V1b receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay
    [PMID: 21428295]
    CHO EC50
    8.3 nM
    Compound: AVP
    Agonist activity at human oxytocin receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay
    Agonist activity at human oxytocin receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay
    [PMID: 21428295]
    CHO-K1 EC50
    15 nM
    Compound: 1, AVP, [Arg8]vasopressin
    Agonist activity at human OT receptor expressed in CHO-K1 cells by luciferase reporter gene assay
    Agonist activity at human OT receptor expressed in CHO-K1 cells by luciferase reporter gene assay
    [PMID: 21688787]
    CHO-K1 EC50
    22 nM
    Compound: AVP
    Agonist activity at human oxytocin receptor expressed in CHO-K1 cells after 5 hrs by firefly luciferase reporter gene assay
    Agonist activity at human oxytocin receptor expressed in CHO-K1 cells after 5 hrs by firefly luciferase reporter gene assay
    [PMID: 24874785]
    COS-1 EC50
    41 nM
    Compound: 2, AVP
    Activity at oxytocin receptor expressed in COS1 cells assessed as IP-one generation by HTRF assay
    Activity at oxytocin receptor expressed in COS1 cells assessed as IP-one generation by HTRF assay
    [PMID: 21117646]
    Flp-In-293 EC50
    4.3 nM
    Compound: 1, AVP, [Arg8]vasopressin
    Agonist activity at recombinant human vasopressin V1b receptor expressed in Flp-In-293 cells by luciferase reporter gene assay
    Agonist activity at recombinant human vasopressin V1b receptor expressed in Flp-In-293 cells by luciferase reporter gene assay
    [PMID: 21688787]
    HEK293 EC50
    0.0035 nM
    Compound: AVP
    Agonist activity at recombinant human V1b receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method
    Agonist activity at recombinant human V1b receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method
    [PMID: 30896946]
    HEK293 EC50
    0.004 nM
    Compound: AVP
    Agonist activity at recombinant human V1a receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method
    Agonist activity at recombinant human V1a receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method
    [PMID: 30896946]
    HEK293 EC50
    0.05 nM
    Compound: 1, AVP, [Arg8]vasopressin
    Agonist activity at recombinant human vasopressin V2 receptor expressed in HEK293 cells by luciferase reporter gene assay
    Agonist activity at recombinant human vasopressin V2 receptor expressed in HEK293 cells by luciferase reporter gene assay
    [PMID: 21688787]
    HEK293 EC50
    0.05 nM
    Compound: AVP
    Agonist activity at human vasopressin V2 expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay
    Agonist activity at human vasopressin V2 expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay
    [PMID: 24874785]
    HEK293 EC50
    0.07 nM
    Compound: 1, AVP, [Arg8]vasopressin
    Agonist activity at recombinant rat vasopressin V1a receptor expressed in HEK293 cells by luciferase reporter gene assay
    Agonist activity at recombinant rat vasopressin V1a receptor expressed in HEK293 cells by luciferase reporter gene assay
    [PMID: 21688787]
    HEK293 EC50
    0.1 nM
    Compound: AVP
    Agonist activity at recombinant human OTR expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method
    Agonist activity at recombinant human OTR expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method
    [PMID: 30896946]
    HEK293 EC50
    0.24 nM
    Compound: 1, AVP, [Arg8]vasopressin
    Agonist activity at recombinant human vasopressin V1a receptor expressed in HEK293 cells by luciferase reporter gene assay
    Agonist activity at recombinant human vasopressin V1a receptor expressed in HEK293 cells by luciferase reporter gene assay
    [PMID: 21688787]
    HEK293 EC50
    0.24 nM
    Compound: AVP
    Agonist activity at human vasopressin V1a expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay
    Agonist activity at human vasopressin V1a expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay
    [PMID: 24874785]
    HEK293 EC50
    4.3 nM
    Compound: AVP
    Agonist activity at human vasopressin V1b expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay
    Agonist activity at human vasopressin V1b expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay
    [PMID: 24874785]
    In Vitro

    AVP (0.01 nM-1 μM) induces Ca2+ increase in Chinese hamster ovary cells expressing rat or human V1b receptors[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    Vasopressin (0.03-0.3 μg/kg; i.p.) potentiates corticotropin release provoked by exogenous corticoliberin and increases corticotropin secretion subsequent to body water loss[2].
    Vasopressin (0.001-0.1 mg/kg; i.p.) potently increases adjacent lying, where rats meeting for the first time lie passively next to each other[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Masse moléculaire

    1084.23

    Formule

    C46H65N15O12S2

    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    Sequence

    Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (Disulfide bridge: Cys1-Cys6)

    Sequence Shortening

    CYFQNCPRG-NH2 (Disulfide bridge: Cys1-Cys6)

    Structure Classification
    Initial Source
    Livraison

    Room temperature in continental US; may vary elsewhere.

    Stockage

    Sealed storage, away from moisture

    Powder -80°C 2 years
    -20°C 1 year

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    Solvant et solubilité
    In Vitro: 

    DMSO : 100 mg/mL (92.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : 50 mg/mL (46.12 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 0.9223 mL 4.6116 mL 9.2231 mL
    5 mM 0.1845 mL 0.9223 mL 1.8446 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Calculateur de molarité

    • Calculateur de dilution

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (2.31 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (2.31 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 25 mg/mL (23.06 mM); Clear solution; Need ultrasonic and warming

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Pureté et documentation

    Purity: 99.65%

    Références

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO 1 mM 0.9223 mL 4.6116 mL 9.2231 mL 23.0578 mL
    5 mM 0.1845 mL 0.9223 mL 1.8446 mL 4.6116 mL
    10 mM 0.0922 mL 0.4612 mL 0.9223 mL 2.3058 mL
    15 mM 0.0615 mL 0.3074 mL 0.6149 mL 1.5372 mL
    20 mM 0.0461 mL 0.2306 mL 0.4612 mL 1.1529 mL
    25 mM 0.0369 mL 0.1845 mL 0.3689 mL 0.9223 mL
    30 mM 0.0307 mL 0.1537 mL 0.3074 mL 0.7686 mL
    40 mM 0.0231 mL 0.1153 mL 0.2306 mL 0.5764 mL
    DMSO 50 mM 0.0184 mL 0.0922 mL 0.1845 mL 0.4612 mL
    60 mM 0.0154 mL 0.0769 mL 0.1537 mL 0.3843 mL
    80 mM 0.0115 mL 0.0576 mL 0.1153 mL 0.2882 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Vos produits récemment consultés:

    Demande en ligne

    Your information is safe with us. * Required Fields.

    Nom du produit

     

    Requested Quantity *

    Nom du demandeur *

     

    Civilité

    Adresse e-mail *

     

    Numéro de téléphone *

    Department

     

    Nom de l'organisation *

    City

    État

    Country or Region *

         

    Remarques

    Bulk Inquiry

    Inquiry Information

    Nom du produit:
    Vasopressin
    Cat. No.:
    HY-B1811
    Quantité:
    MCE Japan Authorized Agent: